Aerie Pharmaceuticals to Announce Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 2, 2016
October 25 2016 - 7:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), (the “Company”),
announced today that its third quarter 2016 financial results will
be released after the market closes on Wednesday, November 2, 2016.
Following the release, the Company will host a live conference call
and webcast at 5:00 p.m. Eastern Time to discuss the Company's
financial results and provide a general business and strategic
update.
The live webcast and a replay may be accessed by visiting the
Company's website at http://investors.aeriepharma.com. Please
connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that
may be needed to access the webcast. Alternatively, please call
(888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen
to the live conference call. The conference ID number for the live
call is 96841619. Please dial in approximately 10 minutes prior to
the call. Telephone replay will be available approximately two
hours after the call. To access the replay, please call (855)
859-2056 (U.S.) or (404) 537-3406 (international). The conference
ID number for the replay is 96841619. The telephone replay will be
available until November 9, 2016.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma and other
diseases of the eye. Aerie's two lead product candidates are
once-daiIy IOP-lowering therapies with novel mechanisms of action
to treat patients with glaucoma or ocular hypertension. The NDA
filing for Rhopressa™ (netarsudil ophthalmic solution) 0.02% was
submitted in the third quarter of 2016. The second product
candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution)
0.02%/0.005%, which is a fixed dose combination of Rhopressa™ and
widely prescribed PGA latanoprost, currently has two Phase 3
registration trials underway, named Mercury 1 and Mercury 2. If
these trials are successful, a Roclatan™ NDA filing is expected to
take place near year-end 2017. Aerie is also focused on the
development of additional product candidates and technologies in
ophthalmology.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161025005027/en/
Aerie PharmaceuticalsRichard Rubino,
908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on
behalf of Aerie PharmaceuticalsAmi Bavishi,
212-213-0006abavishi@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024